FGP
MRVI icon

Freestone Grove Partners’s Maravai LifeSciences MRVI Stock Holding History

Freestone Grove Partners’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-46,144
Closed -$251K – 716
2024
Q4 		$251K Buy
+46,144
New +$297K ﹤0.01% 498

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.06B AUM 19.83% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Freestone Grove Partners's MRVI Position: Q1 2025 in Review

Freestone Grove Partners sold out of Maravai LifeSciences (MRVI) in Q1 2025, closing a stake of 46,144 shares — an estimated $251K sold.

Freestone Grove Partners first reported a position in MRVI in Q4 2024 and held it in 1 quarter. The position peaked at $251K in Q4 2024. 184 funds tracked by Wall St. Rank hold MRVI as of Q1 2025.

  • Freestone Grove Partners reported no remaining Maravai LifeSciences position as of Q1 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 46,144 Maravai LifeSciences shares in Q1 2025, an estimated $251K.
  • Freestone Grove Partners first reported a position in Maravai LifeSciences in Q4 2024 and held it in 1 quarter.
  • Freestone Grove Partners's Maravai LifeSciences position peaked at $251K in Q4 2024.
  • 184 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2025.

Based on Freestone Grove Partners's 13F filing for Q1 2025, filed 15 May 2025.